ReviewThe Indian journal of medical research2018
Review in The Indian journal of medical research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 2 syntheses or guidelines pooled it, 135 citations in OpenAlex.
- Efficacy and safety of Lianhua Qingwen granule combined with azithromycin forFrontiers in pharmacology · 2024Pooled it
- A systematic review of the clinical features of pneumonia in children aged 5-9 years: Implications for guidelines and research.Journal of global health · 2022Pooled it
- Application of Clinical Indicators in the Early Prediction of RefractoryClinical pediatrics · 2026Article
- Glycyrrhizin alleviatesJournal of thoracic disease · 2026Article
- Mapping the Evolution of Diagnostic Research onPathogens (Basel, Switzerland) · 2026Review
- The epidemiology ofNew microbes and new infections · 2026Article
- Research progress on detection technologies for Mycoplasma pneumoniae.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- Comparison between DNA- and RNA-based nucleic acid amplification tests for detecting Mycoplasma pneumoniae in pediatric specimens.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Temporal dynamics of serum Mycoplasma pneumoniae antibodies in patients with acute respiratory infections: a large retrospective study.Annals of clinical microbiology and antimicrobials · 2026Article
- Early Prediction of Necrotizing Pneumonia in Children with Mycoplasma Pneumoniae Pneumonia: Development and Temporal Validation of a Clinical Model.Children (Basel, Switzerland) · 2026Article
- Immunogenicity Evaluation of Six Key Antigens ofVaccines · 2026Article
- In the shadow of COVID-19: changes in the seroprevalence of pediatric Mycoplasma pneumoniae.BMC infectious diseases · 2026Article
- Immune dysregulation inFrontiers in immunology · 2026Review
- Macrolide Resistance and Multilocus Sequence Typing Genotype Analysis ofPublic health weekly report · 2026Article
- Clinical characteristics of community acquired pneumonia due toLe infezioni in medicina · 2026Article
- Comparing differences in onset and clinical manifestations between children and adults withFrontiers in public health · 2026Article
- Epidemiological analysis of six common respiratory pathogen infections in children in Chengdu from 2022 to 2024.Frontiers in pediatrics · 2026Article
- Non-linear associations between inflammatory biomarkers andFrontiers in pediatrics · 2026Article
- Clinical characteristics and cytokine profiles for early prediction of severeFrontiers in pediatrics · 2026Article
- Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lower respiratory tract infections are considered a common cause responsible for morbidity and mortality among children, and Mycoplasma pneumoniae is identified to be responsible for up to 40 per cent of community-acquired pneumonia in children greater than five years of age. Extrapulmonary manifestations have been reported either due to spread of infection or autoimmune mechanisms. Infection by M. pneumoniae has high incidence and clinical importance but is still an underrated disease. Most widely used serologic methods are enzyme immunoassays for detection of immunoglobulin M (IgM), IgG and IgA antibodies to M. pneumoniae, though other methods such as particle agglutination assays and immunofluorescence methods are also used. Detection of M. pneumoniae by nucleic acid amplification techniques provides fast, sensitive and specific results. Utilization of polymerase chain reaction (PCR) has improved the diagnosis of M. pneumoniae infections. Besides PCR, other alternative amplification techniques include (i) nucleic acid sequence-based amplification, (ii) Qβ replicase amplification, (iii) strand displacement amplification, (iv) transcription-mediated amplification, and (v) ligase chain reaction. Macrolides are used as the first-line treatment in childhood for M. pneumoniae infections; however, emergence of macrolide-resistant M. pneumoniae is a cause of concern. Development of a safe vaccine is important that gives protective immunity and would be a major step in reducing M. pneumoniae infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.